Cargando…

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-mutated cutaneous melanoma were randomized 2:1 to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lebbé, Celeste, Dutriaux, Caroline, Lesimple, Thierry, Kruit, Willem, Kerger, Joseph, Thomas, Luc, Guillot, Bernard, de Braud, Filippo, Garbe, Claus, Grob, Jean-Jacques, Loquai, Carmen, Ferraresi, Virginia, Robert, Caroline, Vasey, Paul, Conry, Robert, Isaacs, Richard, Espinosa, Enrique, Schueler, Armin, Massimini, Giorgio, Dréno, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408351/ https://www.ncbi.nlm.nih.gov/pubmed/32610581 http://dx.doi.org/10.3390/cancers12071727

Ejemplares similares

PIMASERTIB AND SEROUS RETINAL DETACHMENTS
por: AlAli, Alaa, et al.
Publicado: (2016)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature
por: Grob, Jean-Jacques, et al.
Publicado: (2017)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies
por: Ravandi, F, et al.
Publicado: (2015)

Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma
por: Becquart, Ondine, et al.
Publicado: (2021)

Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma
por: Couronne, Thomas, et al.
Publicado: (2020)

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
por: Macarulla, T, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France
por: Kandel, Marguerite, et al.
Publicado: (2022)

Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors
por: Brendel, Erich, et al.
Publicado: (2010)

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
por: Ascierto, Paolo Antonio, et al.
Publicado: (2020)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
por: de Weger, Vincent A., et al.
Publicado: (2018)

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013)

Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks
por: Migden, Michael, et al.
Publicado: (2022)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Dacarbazine mediates antimelanoma effects via NK cells
por: Hervieu, Alice, et al.
Publicado: (2013)

Evaluation of protective effect of amifostine on dacarbazine induced genotoxicity
por: Etebari, M., et al.
Publicado: (2015)

Dacarbazine nanoparticle topical delivery system for the treatment of melanoma
por: Hafeez, Abdul, et al.
Publicado: (2017)

Dacarbazine/doxorubicin/vinblastine: Lack of efficacy: case report
Publicado: (2022)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis
por: Gutzmer, Ralf, et al.
Publicado: (2021)

Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS
por: Franzese, Ornella, et al.
Publicado: (2016)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
por: Huynh, Sandra, et al.
Publicado: (2020)

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
por: Budach, W., et al.
Publicado: (1994)

Synthesis and Molecular-cellular Mechanistic Study of Pyridine Derivative of Dacarbazine
por: Amirmostofian, Marzieh, et al.
Publicado: (2013)

Dacarbazine depletes the ovarian reserve in mice and depletion is enhanced with age
por: Winship, Amy L., et al.
Publicado: (2018)

Synthesis, Spectroscopic, and Theoretical Study of Copper and Cobalt Complexes with Dacarbazine
por: Świderski, Grzegorz, et al.
Publicado: (2021)

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
por: Schram, Alison M., et al.
Publicado: (2018)

NRAS mutant melanoma – undrugable?
por: Posch, Christian, et al.
Publicado: (2013)

A randomised, phase II study of intetumumab, an anti-α(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma
por: O'Day, S, et al.
Publicado: (2011)

Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine
por: Machet, Antoine, et al.
Publicado: (2022)

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial
por: Ugurel, Selma, et al.
Publicado: (2017)

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_bf1rmqt6lqtopjpc72tka6hag9